Quarterly ResultAug 6, 2026, 07:13 AM
Monte Rosa Q2 Net Loss $(43.4)M; YTD Loss $(87.9)M
AI Summary
Monte Rosa Therapeutics reported a net loss of $(43.4) million for Q2 2026 and $(87.9) million for the six months ended June 30, 2026. Collaboration revenue decreased significantly year-over-year, while research and development expenses rose. The company bolstered its financial position by raising $324.3 million through a public offering, bringing its total cash, cash equivalents, and marketable securities to $621.1 million, which is expected to fund operations for at least 12 months.
Key Highlights
- Q2 2026 net loss was $(43.4) million, compared to $(12.3) million in Q2 2025.
- Year-to-date net loss was $(87.9) million, compared to $34.6 million net income in prior year.
- Collaboration revenue for Q2 2026 was $9.0 million, down from $23.2 million YoY.
- Research and development expenses increased to $48.0 million in Q2 2026 from $30.7 million YoY.
- Cash, cash equivalents, and marketable securities totaled $621.1 million as of June 30, 2026.
- Net cash used in operating activities was $(81.5) million for the six months ended June 30, 2026.
- Received $324.3 million from an underwritten public offering during the period.
- Liquidity is expected to fund operations for at least 12 months from the issuance date.
Price Impact
More from GLUE